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E-mail address: letizia.brandi@unicam.it (L. BrandSince their introduction in therapy, antibiotics have played an essential role in human society, sav-
ing millions of lives, allowing safe surgery, organ transplants, cancer therapy. Antibiotics have also
helped to elucidate several biological mechanisms and boosted the birth and growth of pharmaceu-
tical companies, generating proﬁts and royalties. The golden era of antibiotics and the scientiﬁc and
economical drive of big pharma towards these molecules is long gone, but the need for effective
antibiotics is increased as their pipelines dwindle and multi-resistant pathogenic strains spread.
Here we outline some strategies that could help meet this emergency and list promising new
targets.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.Antibiotics are, for the vast majority, low molecular weight to the understanding of fundamental biological mechanisms such
(<1000 Da) secondary products of microbial, fungal or plant
metabolism. Several lines of evidence suggest that these or similar
molecules may have been around since the pre-biotic era and may
have played an important role as modulators or effectors of the pri-
meval RNA molecules from which ‘‘modern’’ biological structures
like the ribosomes and riboswitches have evolved. Indeed, the fact
that several antibiotics may have coevolved with RNA is suggested
by the fact that they bind select RNA targets and that some of
them, like the aminoglycosides, can equally inﬂuence ribosomal
decoding and inhibit the second step of Group I T4 phage-derived
td intron splicing, two activities possibly having a common origin
in the ‘‘RNA World’’. Furthermore, a large number of antibiotics
can be synthesized from amino acids and other compounds which
have been detected in meteorites or synthesized in reactions car-
ried out under prebiotic conditions as a result of electric discharge
[1,2 and references therein].
Since their discovery and their ﬁrst therapeutic applications in
the second half of the ‘30s (sulfamides were ﬁrst used around
1935), antibiotics can be credited with having saved millions of hu-
man lives. In addition, the extraordinary contribution given by
antibiotics to the progress of science and to the advancement of
biotechnology should not be ignored. Studies on the mechanism
of action of antibiotics and on both genetics and mechanisms of
bacterial resistance to their action have contributed a great dealchemical Societies. Published by E
i).as DNA duplication, transcription and translation. Genetic charac-
terization of the resistance genes allowed the identiﬁcation of
essential genes such as gyrA (nalA), gyrB (cou) and fus and gene
clusters such as str and of their products. The pioneering work of
the late Luigi Gorini on streptomycin resistance and dependence
and on the ram mutations established for the ﬁrst time the funda-
mental role played by the ribosome in determining decoding ﬁdel-
ity. Finally, antibiotics have been and are tools of invaluable
importance in selection strategies routinely used in genetic
engineering.
Nevertheless, after an initial period in which the detection, bio-
logical, pharmacological and clinical characterization as well as
marketing of new antibiotics have ﬂourished, generating large
proﬁts for the pharmaceutical industry, research on new anti-
infective agents has slowed down considerably. This has resulted
in a long ‘‘innovation gap’’ which extends from 1962, when quino-
lones and streptogramin were ﬁrst applied in human therapy, until
2000, when oxazolinidones were introduced [3,4]. During this per-
iod no major class of antibiotics has been introduced and, to make
matters worse, the decreasing interest and investment in antibiotic
research by the big pharma and the consequent decline in antibi-
otic discovery has been paralleled by the ever more rapid and
frightening spread of antibiotic resistance strains [3,4].
The reasons for the disengagement of the big pharma from
pursuing antibiotic research are mainly non-scientiﬁc and not
health-related, but purely economical. The politics of the regula-
tory authorities, like the US Food and Drug Administration (FDA)lsevier B.V. All rights reserved.
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endowed with non-inferior properties. These issues have been ana-
lyzed and discussed in depth in several articles, e.g. [4–6]. Small
enterprises (biotech) can carry out competent, efﬁcient and high-
quality pre-clinical research. However, since they rely heavily on
rather volatile venture capital, the huge costs connected with clin-
ical trials represent an obstacle and, when this is not the case, any
delay or drawback occurring during the clinical trials results in
economical collapse [4–6]. However, the consequences of this pol-
itics pose a formidable threat on all of mankind, not only on the so-
cially and economically less favoured populations of Africa, Asia
and Latin America, where lack of prevention and degraded hygienic
conditions worsen the effects of the scarcity of therapeutic
resources.
The widespread and increasing occurrence of antibiotic resis-
tance should not represent an alibi for discontinuing antibiotic re-
search, but should instead represent a stimulus to pursue
antibiotic research with renewed energy and enthusiasm. In fact,
alternative approaches to control bacterial infections such as
photodynamic therapy of periodontal and skin diseases, low
temperature plasma treatments, stimulation of host immune
response, use of bacteriophage or bacteriophage components, have
so far proven impracticable and/or futile, being sometimes
restricted to a rather limited number of speciﬁc pathologies.
Indeed, vis-à-vis the worsening of the problems posed by the
rise of bacterial resistance, which is considered by the WHO one
of the three greatest threats to human health, the IDSA (Infectious
Diseases Society of America) has called for a global commitment to
the development of 10 new antibacterial drugs by 2020 [7]. Since it
would not be possible for both large and small enterprises to
escape the logic of the short term proﬁt imposed by the current
economical system and therefore taking for granted the persistent
lack of interest by the big pharma, in spite of some faint indications
of a possible inversion of the current trend [8], only publically
-subsidized research or public research tout-court could meet the
need for new antibiotics.
Once established that new antibiotics are badly needed and
therefore that it is necessary to multiply the efforts to discover
new molecules or to improve the existing ones, strategies which
could offer the best opportunities to reach the goal remain to be
discussed, and both positive and negative experiences of the past
should help in designing them.
Two very important elements that may have a profound impact
on the perspectives of discovering and developing new anti-infec-
tives are the choice of the source of these molecules and the meth-
od of screening adopted.
In the golden age of antibiotics discovery (1940s–1960s), whole
cell screening of mainly natural compounds led to identiﬁcation of
almost all currently known antibiotic classes. In several cases the
natural molecules identiﬁed were improved by chemical modiﬁca-
tions. However, it soon became clear that the easiest-to-discover
anti-infectives had already been identiﬁed. Furthermore, the at-
tempts to ﬁnd antibiotics among natural products encountered a
number of difﬁculties which include the expensive production of
high-quality collections, the elaborate and time consuming process
of puriﬁcation and chemical characterization of the active product
contained in complex extracts, the difﬁculties implicit in the large
scale production of the molecules of interest, the amenability of
the natural drugs to modiﬁcations by medicinal chemistry. For
these reasons the birth of combinatorial chemistry, favored by
the progress of organic synthesis, raised the hope that artiﬁcial
drugs with potential for therapeutic applications could be easily
obtained in a simpler, less expensive way, avoiding the aforemen-
tioned difﬁculties. Thus, about two decades ago (i.e. from late 80’s
to late 90’s) some big pharma such as GW, SKF and Pﬁzer aban-
doned the ﬁeld of natural products in favour of chemical libraries,unlike other companies, such as Merck and Novartis, which had
blockbuster natural drugs in their portfolio. However, HTS of
chemical libraries turned out to be a ﬂop and, short of matching
the high expectations, resulted in a single de novo combinatorial
new chemical entity approved by the US Food and Drug
Administration (FDA), namely the kinase inhibitor Sorafenib
FDA-approved for renal carcinoma. An interesting account of the
various reasons for these failures can be found in the interesting
review written by Payne et al. in 2007 [9].
On the other hand, inspection of the long list of antibiotics
discovered so far clearly indicates that a large majority of them
are either unmodiﬁed or modiﬁed natural products. Furthermore,
natural products still produce the highest hit rate [9]. This is not
surprising insofar as natural products represent more diverse
chemical classes than traditional synthetic and combinatorial
molecules. The natural products derive from common intermedi-
ates which had millions of years to evolve into bioactive
compounds and are produced by and interact with three dimen-
sional molecules that confer upon them steric complexity [10].
These circumstances alone would be sufﬁcient to indicate that
repertoires of natural products were and will remain the best
source of new anti-infectives and the old dilemma natural libraries
vs. chemical libraries seems to have reached its epilogue [11].
Nevertheless, combinatorial synthesis will probably play an impor-
tant role in enhancing the diversity of HTS libraries based on scaf-
folds of proven biological relevance through Diversity-Oriented
Synthesis (DOS) or Biology-Oriented Synthesis (BIOS) to produce
small compound libraries [12 and references therein].
As to the screening strategy and choice of the target, a new
strategy was developed by the mid 90’s with the hope of identify-
ing speciﬁc, essential and suitable bacterial targets and was largely
used by big pharma (e.g. Glaxo-Smith-Kline in Verona). This ap-
proach, mainly triggered by the euphoria generated by the prom-
ises of genomics, relied on the analysis of the increasing amount
of new information obtained from genome sequencing, mainly of
pathogenic bacteria, with the aim of targeting the genes products
responsible for virulence. In spite of the large material efforts
and also as a consequence of a number of strategic mistakes, this
approach failed completely, yielding only a few hits. Bacteria
proved to bypass easily any attempt to inhibit the selected target.
Other likely reasons for the failure were the very short time allot-
ted to the study of each potential target and reliance on chemical
libraries instead of repertoires of natural products.
Thus, the current trend remains that of concentrating on funda-
mental, essential biological targets (e.g. the translational appara-
tus), possibly focusing on speciﬁc steps of these processes
representing unexploited or underexploited antibiotic targets. An
approach of this kind is expected to yield mainly broad-spectrum
antibiotics while the quest for pathogen-speciﬁc inhibitors must
rely on speciﬁc targets of proven relevance.
For what concerns the screening, different strategies have been
suggested and/or applied. A traditional way of proceeding is
through microbiological primary screenings to identify hits having
antimicrobial activity, followed by secondary screenings aimed at
obtaining a better characterization of the hits and at the possible
selection of lead compounds. This type of approach, in its simplest
formulation, although very successful in the past, can be regarded
as outdated since it would likely ‘‘rediscover’’ known inhibitors
and would also miss a large number of potentially interesting mol-
ecules that do not or hardly penetrate the test cells. Thus, im-
proved methods of whole cell screening are necessary. These
include ‘‘smart screening’’ using multiple-resistant ‘‘superbugs’’
[13], tests that allow the in vivo measurement of the inhibition
of a select, partially silenced target with respect to wild type [14]
and genetically modiﬁed cells that produce speciﬁc responses upon
inhibition of a select function [15].
Fig. 1. Translation initiation pathway. (A) 30S initiation complex formation and (B) 70S initiation complex formation. The pathway of the initiator fMet-tRNA formation is
presented in the inset. The established/suggested sites of action of the inhibitors are indicated with the corresponding references. (See above-mentioned references for further
information.)
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large differences in sensitivity may exist among different bacteria.
In general, Gram-negative bacteria are much more difﬁcult targets
for antibiotics than Gram positives, insofar as their outer mem-
brane is more difﬁcult to be penetrated and because multiple kinds
of antibiotics are easily expelled by the efﬂux pumps which are
major non-plasmid-encoded contributors to multidrug resistance.
In fact, it has been shown that the screening of an unbiased library
produces 10–100 times more hits against Staphylococcus aureusthan against Escherichia coli and even more compared to non-fer-
menters such as Pseudomonas aeruginosa. However, different
sensitivity to antibiotics is not restricted to differences between
Gram positive and Gram negative bacteria, but is also observed
among different species of the same genus or among different
strains of the same species, which may have substantial variations
in their genome. In this connection, it seems advisable to perform
the screening on clinical isolates of interest rather than on model
laboratory-tamed strains [16,17].
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is the in vitro screening of select targets. This approach offers the
advantage of identifying inhibitors having the desired biological
activity, independent from their possible failure to penetrate the
cells. If necessary and worthwhile, cell permeability problems
can be bypassed by subsequent chemical modiﬁcations, e.g. by
rendering the inhibitor more hydrophobic or linking it to a
cell-permeable molecule such as a polyamine, a sugar or to
another, already validated antibiotic. We are aware that
approaches of this type have failed in a number of cases, but feel
conﬁdent that in other cases, knowledge-based modiﬁcations
could yield the desired result. In this connection it is perhaps
worth mentioning the case of the P-site inhibitor GE81112
[18,19] (see also below). This tetrapeptide antibiotic displays a
MIC 0.1 lg/ml in minimal medium but is completely ineffective
in rich medium due to competition by other peptides present in
the milieu for the peptide pump OPP which is responsible for its
entry in both Gram positive and Gram negative cells. Appropriate
chemical modiﬁcations introduced in a permissive part of the mol-
ecule were found to allow the entry of GE81112 bypassing the OPP
system and to reduce its MIC in rich medium from 500 to 8 lg/
ml without altering either nature of the target or mechanism of ac-
tion in clinical isolates of P. aeruginosa, or affecting the encouraging
results of the cell toxicity tests (unpublished results). Although
economical difﬁculties have prevented Vicuron Pharmaceuticals
from pursuing further these preliminary trials, the outcome of
these experiments left the impression that an additional effort
along the aforementioned lines could have yielded the desired re-
sult of ensuring the efﬁcient entry of the inhibitor into the cell.
Another approach to favour the entry of recalcitrant inhibitors
into the cells could be their complexation with cyclodextrin deriv-
atives. Such complexation is expected to improve also the chemical
stability of the inhibitors and to increase both their absorption and
bioavailability. The choice of the best type of cyclodextrin to be
used for antibiotic complexation could be empirically determined
in each case depending upon their performance.
Ideally, in vitro screening of select targets should focus on
essential cell functions performed by a complex machinery with
a well known 3D structure so that rational design and ligand-based
design can be applied to improve the performance of the inhibitor.
From this point of view ribosomal subunits, RNA polymerase, ami-
noacyl-tRNA synthetases and riboswitches would appear to repre-
sent ideal targets. Along these lines, a target that seemed to be
ideal insofar as being essential and bacteria-speciﬁc was the metal-
loenzyme peptide deformylase (PDF) which removes the N-formyl
group from the N-terminal formyl methionine from bacterial but
not from mitochondrial translational products [20 and references
therein]. However, to the best of our knowledge the development
of PDF inhibitors has been recently discontinued, likely due to
the toxicity of these compounds which may interfere with the
activity of eukaryotic metalloenzymes. Obviously, the target-direc-
ted approach is expected to see only a limited number of inhibitors
directed against a narrow window of biological activities; never-
theless, if the chosen target is an unexploited or underexploited
function (like, for instance, translation initiation and termination)
the potential advantage of this approach is that of minimizing
the rediscovery of known antibiotics and identifying instead novel
inhibitors, possibly belonging to new classes of molecules for
which no bacterial resistance or cross-resistance has developed.
These target-based HTS can be combined with microbiological
screenings whereby the in vitro-detected hits are ‘‘cherry-picked’’
and subsequently screened for their antibacterial activity using a
panel of representative organisms, or may be applied to test hits
‘‘cherry-picked’’ following a microbiological HTS. Both methods
could prove successful. Indeed, in our hands upon screening ‘‘only’’
25,000 natural extracts the ﬁrst approach identiﬁed two newinhibitors, the aforementioned GE81112 [18,19] and GE82832
[21] while following a microbiological screening of 89 000 extracts
the second strategy yielded GE107558 [22]. However, the target-
related HTS approach can result in rather frustrating results, as
experienced by several big (e.g. Glaxo Smith Kline, Pﬁzer) and
small (e.g. Cubist) pharma after large screening campaigns. In spite
of this, we do not share the opinion that the target-related screen-
ing approach is scientiﬁcally worthless and uneconomical, pro-
vided that the targets are carefully selected and validated, that
the methods of primary screening are further miniaturized and
have the characteristics of being simple, speciﬁc, robust, sensitive,
inexpensive, reproducible and guarantee reliable results, possibly
yielding some key information concerning the inhibition mecha-
nism [23,24]. Another condition to avoid the past failures is that
the screening must involve libraries of natural or natural-like
compounds.
Finding new antibiotics through the aforementioned strategies
is not the only way of replenishing the pharmacy shelves with
effective anti-infectives. An alternative, commonly used approach,
has been that of resorting to medicinal chemistry to modify antibi-
otics already approved in therapy with the aim of improving the
properties and or bypassing the mechanism of resistance or to
‘‘revive’’ inhibitors discovered in the past but never further
developed.
Examples of the ﬁrst approach are the successful chemical mod-
iﬁcations introduced into beta-lactams, tetracyclines, aminoglyco-
sides, etc. while an example of the latter approach is exempliﬁed
by the recent, successful case of Daptomycin. This drug, discovered
in the 80’s, was initially neglected and ﬁnally approved by the US
FDA in 2003 after being developed by Cubist Pharmaceuticals. As
pointed out in a recent article a situation similar to that of Dapto-
mycin may apply also to other molecules such as the macrolactone
Diﬁmicin, which inhibits RNA transcription and the cyclic lipode-
capetide Friulimicin, which inhibits cell wall synthesis [25].
Another successful approach consists in the chemical modiﬁca-
tion and improvement of select, small molecules through the so-
called fragment-based drug discovery (FBDD). As mentioned
above, the failure of HTS campaigns was caused, at least in large
part by the use of inadequate chemical libraries which had a too
limited chemical diversity and physicochemical properties for anti-
biotic screening. To overcome these limitations and to increase the
hit rates in recent years the FBDD approach has been developed. In
this method libraries consisting of small (i.e. <300 Da), moderately
lipophilic, highly soluble, molecules are screened. Such molecules
are more likely to bind to select targets than larger molecules
and are prone to be further developed. Biochemical assays, X-ray
crystallography, NMR spectroscopy, mass spectrometry, surface
plasmon resonance can be used for the detection of active frag-
ments which can be later optimized for potency (increasing the
binding afﬁnity usually by structure-guided modiﬁcations) and
for drug-like properties. The potentiality of FBDD is proven by
the entry in clinical trials of several leads active against different
targets, especially cancer targets, obtained using this approach. In
antibiotic discovery, the FBDD strategy is producing interesting
results such as the amino-oxazole inhibiting Gram negative biotin
carboxylase [26] and the inhibitors of protein tyrosine phosphatase
PtpA or antigen 85C of Mycobacterium tuberculosis [27,28].
Another winning approach could be that of rationally re-design-
ing existing antibiotics or designing novel antibiotic scaffolds
exploiting the already available or prospective structural data
derived from crystallographic studies of essential biological macro-
molecules and/or macromolecular complexes such as riboswitches
and ribosomes in combination with predictive computational
chemistry. A successful approach along these lines is that used
by Rib-X with Radezolid (RX-1741), an oxazolidinone antibiotic
(in phase 2 clinical trial) that exhibits activity against methicil-
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displaying properties superior (wider spectrum and stronger po-
tency) to those of Zyvox (linezolid). Radezolid was knowledge-
base developed exploiting the atomic 3D structure of the 50S ribo-
somal subunit.
Another promising approach followed by scientists at Rib-X and
elsewhere is the generation of chimeric antibiotics. Thus, a chime-
ric molecule composed of elements of two cyclic peptide antibiot-
ics, the virginiamycin Streptogramin B, a 50S ribosomal subunit
inhibitor, and tyrocidine, a compound that destroys the cell mem-
brane was developed. The resulting chimeric antibiotic proved toFig. 2. Translation elongation pathway. (A) Steps involved in the peptide bond formation
the inhibitors are indicated with the corresponding references. (See above-mentioned rbe able to bypass two of the known resistance mechanisms against
Streptogramin B, namely the lyase Vgb-catalyzed hydrolysis and
target modiﬁcation by Erm-dependent 23S rRNA methylation
[29]. Other interesting chimerae are the ‘‘AU-FQ’’, hybrid molecules
between anilinouracils which inhibit the Gram-positive-speciﬁc
DNA polymerase pol IIIC and the gyrase inhibitors ﬂuoroquino-
lones which are at least 15 times more active than the correspond-
ing isolated compounds and proved to be active against both
AU- and FQ-resistant Gram-positive bacteria [30].
As mentioned above, widespread antibiotic resistance against
all known classes of natural and synthetic compounds is one ofand (B) EF-G dependent translocation. The established/suggested sites of action of
eferences for further information.)
Fig. 3. Translation termination and ribosome recycling pathway. The established/suggested sites of action of the inhibitors are indicated with the corresponding references.
(See above-mentioned references for further information.)
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occurrence is impossible in light of the high density of resistance
genes in the environment, of facile horizontal transfer of these
genes and by the adaptive value that they confer upon the bacteria
[31]. Aside from using antibiotics more responsibly and trying to
exploit the severe loss of ﬁtness that antibiotic resistance may
cause [32], the spread and the emergence of resistant bacteria
and the consequences of the resistance can be mitigated by the
development and use of entirely new antibiotics or of modiﬁed
versions of antibiotics whose efﬁcacy has been substantially re-
duced by the emergence of resistance. Some of these approaches
have been mentioned above. To cope with vancomycin resistance,
one of the most serious threats, several novel second-generation
lipoglycopeptides that inhibit bacterial cell wall synthesis have
been developed. Among these, the most promising appear to be:
(a) Teicoplanin (Targocid), an antibiotic produced by Actinoplanes
teichomyceticus with an activity spectrum similar to that of vanco-
mycin, being active against Gram-positive bacteria, includingMRSA and Enterococcus faecalis; (b) Telavancin, a synthetic vanco-
mycin derivative which depolarizes and disrupts bacterial
membranes. This antibiotic has been approved by the FDA for
treatment of complicated skin and skin-structure infections (cSSSI)
caused by susceptible Gram-positive bacteria, including MRSA and
methicillin-susceptible (MSSA) strains of S. aureus; (c) Dalbavancin
(Zeven), initially developed at Biosearch Italia (later Vicuron
Pharmaceuticals), which is active against MRSA and a variety of
other Gram-positive pathogens; (d) Oritavancin (also known as
LY333328) a semi-synthetic glycopeptide with a vancomycin-
similar structure which was developed for the treatment of serious
Gram-positive infections. Both Dalbavancin and Oritavancin await
more convincing results from phase 3 clinical trials before
approval.
Antibiotics can be classiﬁed according to different criteria such
as their economic impact, origin, chemical nature, spectrum of
action, therapeutic application or nature of target, the latter being
the criterion that we use. By far the main antibiotic target is the
Table 1
Select list of underexploited antibiotic targets and some of their inhibitors.
Targets Antibiotic Comments Ref.
Aminoacyl-tRNA
synthetase
Leu-tRNA synthetase
(LeuRS)
AN3365 Boron-based new antibiotic; developed by Anacor; new mechanism of
action; binds stably LeuRS editing site forming adduct with ribose A76;
successfully completed Phase 1 clinical trials; active against AR
opportunistic Gr-neg pathogens, including P. aeruginosa, E. coli, K.
pneumoniae, P. vulgaris, S. marcescens, Providentia spp, Enterobacter spp and
Citrobacter spp
a
Phe-tRNA synthetase
(PheRS)
Benzyl Phenyl Ethers (BPEs) Inhibits PheRS of H. inﬂuenzae and S. pneumoniae [56]
Met-tRNA synthetase
(MetRS)
REP8839 (derivative REP3123) Diaryldyamine; binds at or near Met binding site and inhibits MetRS of
MRSA and S. Pyogenes; less active on Gr-neg bacteria; not active on mice
liver MetRS
[36]
Membranes LpxC [UDP-3-O-(R-3
hydroxymyristoyl)-N-
Ac-glucosamine
deacetylase]
CHIR-090 Catalyzes the committed step of lipid A biosynthesis; active against broad
range Gr-neg bacteria; may be developed to control Pseudomonas
aeruginosa infections
[57]
LptD POL7080 Induces perturbation of a crucial LPS transport function of LptD in P.
aeruginosa
[58]
Membrane integrity XF-73 Depolarizes and permeabilizes membranes, disrupting multiple cellular
process; no cross-resistance in Daptomycin-resistant strains
[59]
Membrane-bound
ATPase (AtpE subunit)
TMC207 (R207910) Speciﬁc against M. tuberculosis [60]
Gyrase DNA topology
control
GyrA GSK299423 Mechanism of inhibition distinct from that of ﬂuoroquinolones and
novobiocin; bactericidal against a variety of MDR bacteria, including MRSA
and quinolone-resistant pathogens
[61]
GyrB QPT-1 Synthetic barbituric acid derivative; mechanism of inhibition distinct from
ﬂuoroquinolones and novobiocin; active against a broad spectrum of
pathogenic AR bacteria
[62]
Transcription RNA polymerase
(RNAP)
Lipiarmycin (Diﬁmicin,
Fidaxomicin, OPT-80, PAR-101)
Developed by Optimer Pharmaceuticals; new class of macrocycles from
Actinoplanes deccanensis; inhibits open-complex formation preventing
ssDNA loading at the active-site cleft of RNAP; bactericidal against C. difﬁcile
[63]
RNA polymerase
(RNAP)
Myxopyronin a-Pyrone produced by Myxococcus fulvus; new class of RNAP inhibitors;
binds to switch 2 region of RNAP b-subunit, away from rifampicin; possible
treatment of tuberculosis
[64]
Fatty acid (FA)
synthesis
Fab I (enoyl-ACP
reductase) essential for
FA biosynthesis
AFN-1252 (API-1252) Currently in Phase 1 trial; very limited activity spectrum, speciﬁc against
MSSA and MRSA but not other Gr-pos or Gr-neg bacteria; inhibition may be
bypassed in presence of exogenous fatty acids
[65]
FabF (b-ketoacyl-(acyl-
carrier-protein (ACP))
synthase I/II (FabF/B)
Involved in cell
membranes
biosynthesis
Platensimycin New class natural product of Streptomyces platensis containing a pentacyclic
motif with a cyclic ether ring; developed by Merck; platensimycin and
platencin have a 3-amino-2,4-dihydroxy benzoic acid unit in common and
different ketolide portions; blocks enzymes involved in condensation steps
in fatty acid biosynthesis; active against Gr-pos, including MRSA, VAR
Enterococci and linezolid- and macrolide-resistant pathogens. Inhibition
may be bypassed in presence of exogenous fatty acids
[66]
FabF/FabH Platencin Differs from platensimycin for presence of a tetracyclic motif and absence
of ether ring; targets both FabH and FabF; broad-spectrum Gr-pos bacteria;
more active than Platensimycin against VAR E. faecium and efﬂux-negative
E. coli (tolC), less active against S. pneumoniae
[67]
Biotin carboxylase (BC)
(subunit of the
multisubunit enzyme
acetyl-CoA
carboxylase)
Pyrido-pyrimidines Active against Gr-neg pathogens such as H. inﬂuenzae and M. catarrhalis [68]
Tetrahydrofolate
(THF)
biosynthesis
ADC synthase/ADC
lyase
Abyssomicin C Complex polyketide-type antibiotic from a Verrucosispora strain; inhibits
synthesis of p-aminobenzoate in THF biosynthetic pathway
[69]
Cell division Ftsz PC190723 Small synthetic molecule; inhibits FtsZ and prevents cell division;
bactericidal against MRSA and MDRSA; can cure mice infected with a lethal
dose of S. aureus
[70]
Quorum sensing
dependent
virulence
QseC (His kinase sensor
of host and bacterial
signaling molecules
activating virulence
cascade)
LED 209 Synthetic benzenesulphonamide derivative; given before infection inhibits
virulence, not growth of enterohemorrhagic E. coli, S. typhimurium and F.
tularensis
[71]
Protein quality
control
ClpP (caseinolytic
peptidase P)
Acyldepsipeptides (ADEPs) Targets catalytic core of peptidase caseinolytic protease P (ClpP) causing a
complete functional reprogramming of the Clp–protease complex affecting
ClpP-dependent general and regulatory proteolysis; bactericidal activity
against MDR Gr-pos bacteria S. aureus, S. pneumoniae and Enterobacteriaceae
[72]
Purine biosynthesis
and transport
Guanine riboswitch PC1 Novel antimicrobial; crystal structure-based rationally designed pyrimidine
compound; binds guanine riboswitch in guanine-starved cells; bactericidal
against a subgroup of bacterial species including S. aureus and C. difﬁcile
[73]
Abbreviations: Gr-neg = Gram negative; Gr-pos = Gram positive; AR = antibiotic resistant; MDR = multi drug resistant; MRSA = methicillin resistant Staphylococcus aureus;
MSSA = methicillin sensitive Staphylococcus aureus; MDRSA = multi drug resistant Staphylococcus aureus; VAR = vancomycin resistant; cSSSI = complicated skin and skin
structure infection.
a Information available in http://www.anacor.com/pdf/ICAAC2010F1-1637.pdf; http://www.jmilabs.com/data/posters/ICAAC2010/F1-1639.pdf.
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inhibitors being directed against its function; here below we pres-
ent a graphic summary of the sites and/or steps within the initia-
tion (Fig. 1), elongation (Fig. 2) and termination (Fig. 3) pathways
of protein synthesis affected by these antibiotics. As seen from
these ﬁgures, some speciﬁc molecular structures or translational
steps such as the A-site decoding region of the 30S subunit and
the peptidyltransferase center or the adjacent peptide exit tunnel
of the 50S subunit, are much more frequently targeted by the
inhibitors than others so that at least some of them (e.g. aminoacy-
lation and translation initiation) can be regarded as being underex-
ploited and offer the opportunity of ﬁnding new inhibitors for
which no resistance has yet been developed. This seems to be
the case, for instance for the Class I thiopeptide compounds (i.e.
PA–PD series, Thiazomycin and Philipimycin) which target a differ-
ent region of the ribosome, namely the GTPase-associated region
or translation factor binding site, where they interact with both
rRNA and ribosomal protein L11 [53–55]. Among these antibiotics
are the four inhibitors which are presently under investigation in
our laboratory, namely G1 (unpublished results), GE81112
[18,19] (Fig. 1) and GE82832 [21] and GE107558 [22] (Fig. 2).
Aside from translation, a select list of unexploited or underex-
ploited targets is presented in Table 1 along with a non-exhaustive
list of antibiotics which interfere with them and are, therefore, in
our opinion, of particular interest insofar as they may represent
good candidates for the development of new anti-infectives, either
as such or upon appropriate structural modiﬁcations.
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